A$60m placement, with the ability to accept overs Placement Price: A$2.05 per share
Discount
- Discount to last close of A$2.180/sh: 6.0%.
- Discount to 5 trading day VWAP of A$2.151/sh: 4.7%.
- Discount to 10 trading day VWAP of A$2.090/sh: 1.9%.
Artrya Limited (ASX:AYA)
AYA2
Lead Manager
Contact - Jake Grbavac
0474 484 982
jake@liquidity.com.au
Offer Price
A$2.050
per share
Offer Size
A$60,000,000
Offer Details
Issue Price (Per Share)
A$2.050
Discount
37.12%
Offer Size
A$60,000,000
Shares Available
29,268,292
Documents & Downloads
Company Overview
Artrya Limited is an Australian medical technology company focused on developing and commercialising AI-powered solutions for the diagnosis and management of coronary heart disease. Its flagship product, Salix, uses artificial intelligence to analyse cardiac imaging and identify vulnerable plaque, a key predictor of heart attacks that is often missed by traditional methods. By supporting earlier and more accurate diagnosis, Artrya aims to improve patient outcomes and reduce the global burden of cardiovascular disease.
Unique point-of-care solution for real-time coronary heart disease assessment and patient triage
- Cloud based AI platform for point of care analysis of CCTA scans without human intervention.
- Detailed plaque and flow analysis in under 10 minutes – specifically high-risk plaque for improved treatment.
- Single reporting platform – consolidated CCTA reporting with flexibility to edit assessments.
- Transforms CCTA imaging into a profitable modality for health systems versus a cost centre.
- Seamlessly fits into workflow – agnostic system that is simple to deploy use and update.
Salix® is a single platform solution built to scale
- FDA cleared ‒ Salix® Coronary Anatomy (US$325 CPT1 per scan). ‒ Salix® Coronary Plaque (US$950 CPT1 per scan).
- Salix® Coronary Flow Module – anticipated FDA clearance 1Q2026.
- Focused on US with minimal competition, attractive reimbursement and largely greenfield market.
- Large addressable US market – US$4.4bn serviceable
SAPPHIRE study – Salix® plaque analysis to identify patients at high risk of heart attack and improve treatment
- 6 – 8 high volume U.S. Centres – 3 phased retrospective study.
- Piedmont Healthcare first participant.
- Predict future adverse events and improve treatment.
- Clinical validation, awareness and adoption.
- Accelerate commercial adoption in U.S. hospitals.
Phased commercialisation building foundations for scale & expansion into global healthcare system
- US commercial traction started with launch partners: ‒ First 5-year commercial contract with Tanner Health for SCA & additional agreements in the pipeline. ‒ Cone Health & Northeast Georgia Health System have been U.S. validation partners since 2024.
- Expand product suite and commercialise Salix® Plaque and Flow modules.
- Leverage SAPPHIRE study to target large enterprise contracts with study collaborators.
Use of Funds
Funds to be applied to US commercial expansion, customer success and support, market access enablement, product development, research & development and working capital
Disclaimer
This site does not constitute an offer, recommendation, or invitation to any person, nor does it purport to provide all of the information an interested party may require in order to investigate the affairs of Artrya Limited. This site is provided for information only and has not been prepared with the intention that the recipient should rely on it. Liquidity Technology Pty Ltd ("Liquidity") does not make any representation in relation to the contents of this site or give any assurances as to the accuracy or the degree of care or diligence used in preparing this document. The information, data, and advice herein is provided to recipients on the clear understanding that Liquidity nor any of its representatives, directors, officers, employees, agents, or advisers makes any representation or warranty about its accuracy, reliability, completeness, or suitability for any particular purpose and does not accept liability (including, but not limited to, for any expenses, losses, damages, and/or costs (including, but not limited to, indirect or consequential damage)) nor take any responsibility of any kind whatsoever (including, but not limited to, whether in contract, tort, financial or otherwise) for the information, data, or advice contained in or for any omission or for any other information, statement, or representation provided to any recipient (including, but not limited to, as a result of information, data, or advice being inaccurate, unreliable, incomplete, or unsuitable in any way and for any reason whatsoever). Users of this site must conduct their own investigation and analysis regarding any information, statement, or representation contained or provided to any recipient or its associates by Liquidity or any of the Liquidity Personnel. Each recipient waives any right of action, which it has now or in the future against Liquidity or any of the Liquidity Personnel in respect of any errors or omissions on or from this site, however caused. All rights are reserved. If the whole or any part of a provision of this "Notice and Disclaimer" is invalid, illegal, or unenforceable, then such provision will be severed and neither that part or provision or its severance will affect the validity or enforceability of the remaining parts or provisions.
Disclosure of Interest: Liquidity receives commission from dealing in securities and its introducers of business may directly share in this commission. Liquidity and its associates may hold shares in Artrya Limited.
